Back to School: How biopharma can reboot drug development. Access exclusive analysis here

OxiGene, Techniclone deal

The companies signed a letter of intent to form a

Read the full 102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE